Results 111 to 120 of about 436,478 (164)

The Multifaceted Roles of STAT6: Implications for Precision Immunotherapeutics. [PDF]

Immunotargets Ther
Narvel H, Nishizaki D, Kato S, Kurzrock R.   +3 more
europepmc   +1 more source

Refractory Hypereosinophilic Syndrome With Clonal T-Cell Receptor Rearrangement Treated With JAK Inhibition Following Incomplete Response to IL-5 Blockade. [PDF]

Case Rep Hematol
McKaughan KW, Truong PV, Bongers G.
europepmc   +1 more source

Upadacitinib for refractory cutaneous disease in a patient with tif1γ-positive dermatomyositis. [PDF]

An Bras Dermatol
Demir Y, Ogun H, Sulu B, Oba MC, Seyahi E.   +4 more
europepmc   +1 more source

Eczema Molluscatum in a Patient With Atopic Dermatitis on Upadacitinib and Methotrexate. [PDF]

Cureus
Wiesenhofer H, Waldal G, Patel P, Buttars B, Hamann CR.   +4 more
europepmc   +1 more source

JAK inhibitors and adverse cardiovascular events: Class effect or molecule-specific risk? [PDF]

Front Pharmacol
Radić M, Bečić T, Prižmić PŠ, Pavlović MR, Vučković M, Radić J, Borovac JA, Fajkić A, Belančić A.   +8 more
europepmc   +1 more source

Let-7c-3p Suppresses Ovarian Cancer Progression by Targeting S100A6 and Inhibiting JAK-STAT Signaling. [PDF]

Cancers (Basel)
Yuan B, Huang X, Li J, Su Y, Li S, Yuan H, Bi Y, Bei P, Wang J, Han M.   +9 more
europepmc   +1 more source

Efficacy and tolerability of janus kinase inhibition strategies for moderate-to-severe Crohn's disease: A systematic review and bayesian network meta-analysis. [PDF]

Ther Adv Gastroenterol
Wazir HU, Mehta K, Shabbir MS, Islam MR, Maaz M, Muzaffar M, Ehsan N, Aliha S, Chauhan A, Khurram A, Saffouri G.   +10 more
europepmc   +1 more source

Howard, JAK

, 2016
Howard, JAK
core  

Successful treatment of coexisting alopecia areata and hidradenitis suppurativa with upadacitinib. [PDF]

An Bras Dermatol
Moreira Gomes P, Costa R, Pedrosa A, Lisboa C.   +3 more
europepmc   +1 more source

The two faces of JAK-STAT. [PDF]

Elife
Lu Q, Zhang Y.
europepmc   +1 more source